Slide JOINT UNIT UPV-CIPF
NANOMEDICINE
Ramón Martínez Máñez





The work of our unit is mainly based on the development and application of new nanomedicines and probes for diagnosis, prognosis, and therapy in various diseases. Our lines of research include:

-Development of nanomaterials with “molecular gates” for the detection of biomolecules and/or for the controlled release of drugs: Our objective is to develop nanosystems based on mesoporous silica nanoparticles, equipped with molecular gates that can retain a cargo within their pore system and deliver it by applying a specific stimulus (redox changes, pH changes, enzymes, light, magnetic fields, etc.). The development of these nanosystems allows the achievement of a controlled release of the cargo in the presence of the substance of interest or the controlled drug delivery in the diseased tissue, thus reducing unwanted side effects. Another of the lines of our research in the field of controlled cargo release includes the development of nanoparticles capable of communicating with each other or with cells through the exchange of chemical messengers, capable of cooperative work (nanorobots), or with autonomous movement capacity.

-Development of molecular probes: Another of the group’s lines of research is based on the development of chemical molecular probes for the detection of molecules or biomarkers of interest both in vitro and in vivo using colorimetric or fluorometric methods.

Presentation

Get to know us better

Research Staff

The people who make it all possible

Eloisa Jantus Lewintre

Carlos Camps Herrero

Silvia Calabuig Fariñas

Macarena Ferrero Gimeno

Jose Vicente Bagan Sebastian

Ricardo Guijarro Jorge

Miguel Martorell 

Ana Blasco Cordellat

Alfonso Berrocal Jaime

Vega Iranzo González-cruz

Eva Escorihuela Alares

Andrea Moreno Manuel

Susana Torres Martinez

Publications

Our scientific contributions

dPCR application in liquid biopsies: divide and conquer
A. MORENO-MANUEL, S. CALABUIG-FARINAS, A. OBRADOR-HEVIA, A. BLASCO, A. FERNANDEZ-DIAZ, R. SIRERA, C. CAMPS and E. JANTUS-LEWINTRE
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021 Jan,  Vol. 21,  pag. 3-15

CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer
A. MORENO-MANUEL, E. JANTUS-LEWINTRE, I. SIMOES, F. ARANDA, S. CALABUIG-FARINAS, E. CARRERAS, S. ZUNIGA, Y. SAENGER, R. ROSELL, C. CAMPS, F. LOZANO and R. SIRERA
Translational Lung Cancer Research, 2020 Aug,  Vol. 9,  pag. 1074

Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.
Camps C, Badia X, García-Campelo R, García-Foncillas J, López R, Massuti B, Provencio M, Salazar R, Virizuela J and Guillem V
Jco Oncology Practice, 2020 Mar,  Vol. 16,  pag. e298-e305

Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, Pedraz C, Cui J, Yang J, Miao J, Sun R, Bracht JWP, Ito M, Codony-Servat J, Karachaliou N, Aguilar A, Rosell R and Cao P
Annals of Translational Medicine, 2019 Nov,  Vol. 7,  pag. 651-651

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer
Herreros-Pomares A, de-Maya-Girones JD, Calabuig-Fariñas S, Lucas R, Martínez A, Pardo-Sánchez JM, Alonso S, Blasco A, Guijarro R, Martorell M, Escorihuela E, Chiara MD, Duréndez E, Gandía C, Forteza J, Sirera R, Jantus-Lewintre E, Farràs R and Camps C
Cell Death & Disease, 2019 Sep,  Vol. 10,  pag. 660-660

FUNDING

Thank you for supporting us